JPRN-UMIN000020837已完成未知
Effect of Additional pertuzumab for the post treatment in Patients with HER2 positive locally advanced/ metastatic Breast Cancer Who Were Previously Treated with pertuzumab - Phase II study - - Clinical evaluation of re-administratoin of additional pertuzumab (SBP-08: Beyond pertuzumab study)
Setouchi Breast Project Comprehensive Support Organization0 个研究点目标入组 30 人开始时间: 2016年2月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1 pretreated with all of VNR, PTX and ERI 2 allergic for VNR, PTX, ERI, polyoxyethylene castor oil, CHO or recombinant humanized monoclonal antibody 3 symptomatic brain metastasis 4 pregnancy or breast feeding or unwilling to contraception 5 uncontrolled hypertension, symptomatic heart failure, unstable angina, severe arrhythmia or acute myocardial infarction within 12 months 6 obvious pulmonary fibrosis or interstitial pneumonia 7 EF <50% 8 active infection 9 no other severe comorbidity 10 no another active cancer 11 other inappropriate patients
研究者
相似试验
招募中
不适用
Observational study of Pertuzumab in combination with Trastuzumab and Docetaxel in patients with metastatic HER2-positive breast cancer that have the history of Trastuzumab treatmentmetastatic breast cancerJPRN-UMIN000012444Osaka City University Graduate School of Medicine20
已完成
3 期
APHINITYBreast CancerJPRN-jRCT2080221752Chugai Pharmaceutical Co., Ltd.4,800
已完成
不适用
A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-121-08PRODUCTOS ROCHE Q.F.S.A.,9
进行中（未招募）
2 期
Extension study for HER2 amplified advanced solid tumors (JUPITER ES)JPRN-jRCTs031220444Ikeda Sadakatsu3
进行中（未招募）
1 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTAEUCTR2012-002556-17-FRICANCER208